EntryPoint Capital’s Benitec Biopharma BNTC Stock Holding History

EntryPoint Capital’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Sell	15,048 -9,274	-38%	-$110K	0.05%	696
2026 Q1	$259K	Buy	+24,322	New	+$282K	0.08%	530

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

EntryPoint Capital's BNTC Position: Q2 2026 in Review

EntryPoint Capital reduced its Benitec Biopharma (BNTC) stake by 38% in Q2 2026, selling an estimated $110K and leaving 15,048 shares worth $201K. The position accounts for 0.05% of the portfolio, ranked #696.

EntryPoint Capital first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. The position peaked at $259K in Q1 2026. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

EntryPoint Capital held 15,048 shares of Benitec Biopharma worth $201K as of Q2 2026.
EntryPoint Capital sold 9,274 Benitec Biopharma shares in Q2 2026, an estimated $110K.
Benitec Biopharma made up 0.05% of EntryPoint Capital's portfolio in Q2 2026, its #696 holding.
EntryPoint Capital first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
EntryPoint Capital's Benitec Biopharma position peaked at $259K in Q1 2026.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.